Tranexamic acid and supportive measures to treat wasting marmoset syndrome

Takuro Yoshimoto, Kimie Niimi, Eiki Takahashi

研究成果: ジャーナルへの寄稿学術誌査読

7 被引用数 (Scopus)


Wasting marmoset syndrome (WMS) has high incidence and mortality rates and is one of the most important problems in captive common marmoset (Callithrix jacchus) colonies. Despite several reports on WMS, little information is available regarding its reliable treatment. We previously reported that marmosets with WMS had high serum levels of matrix metalloproteinase 9 (MMP9). MMP9 is thought to be a key enzyme in the pathogenesis of inflammatory bowel disease, the main disease state of WMS, and is activated by plasmin, a fibrinolytic factor. In a previous study, treating mice with an antibody to inhibit plasmin prevented the progression of inflammatory bowel disease. Here we examined the efficacy of tranexamic acid, a commonly used plasmin inhibitor, for the treatment of WMS, with supportive measures including amino acid and iron formulations. Six colony marmosets with WMS received tranexamic acid therapy with supportive measures for 8 wk. The body weight, Hct, and serum albumin levels of these 6 marmosets were increased and serum MMP9 levels decreased after this regimen. Therefore, tranexamic acid therapy may be a new and useful treatment for WMS.

ジャーナルComparative Medicine
出版ステータス出版済み - 12月 2016

!!!All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)
  • 獣医学(全般)


「Tranexamic acid and supportive measures to treat wasting marmoset syndrome」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。